Home > Insider Trading > Filing (0001209191-22-047085)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1496323	Igm Biosciences Inc.	IGMS	Pharmaceutical Preparations (2834)	770349194

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1787362	Bruce Keyt	C/O Igm Biosciences, Inc. 325 E. Middlefield Road Mountain View CA 94043	Chief Scientific Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2022-08-18	10,000	$0.93	49,489	No	4	M	Direct
Common Stock	Disposition	2022-08-18	10,000	$22.54	39,489	No	4	S	Direct
Common Stock	Acquisiton	2022-08-19	8,700	$0.93	48,189	No	4	M	Direct
Common Stock	Disposition	2022-08-19	8,700	$22.82	39,489	No	4	S	Direct
Common Stock	Acquisiton	2022-08-22	6,300	$0.93	45,789	No	4	M	Direct
Common Stock	Disposition	2022-08-22	6,300	$20.71	39,489	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2022-08-18	10,000	$0.00	10,000	$0.93
Common Stock	Stock Option (right to buy)	Disposition	2022-08-19	8,700	$0.00	8,700	$0.93
Common Stock	Stock Option (right to buy)	Disposition	2022-08-22	6,300	$0.00	6,300	$0.93

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
123,756	2023-01-12	No	4	M	Direct
115,056	2023-01-12	No	4	M	Direct
108,756	2023-01-12	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	1,013	Indirect	See footnote

Footnotes

The option exercises and sales were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.
This transaction was executed in multiple trades at prices ranging from $22.35 to $22.63. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
This transaction was executed in multiple trades at prices ranging from $22.40 to $23.16. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
This transaction was executed in multiple trades at prices ranging from $20.50 to $21.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
The shares are held directly by the reporting person's spouse.
The shares subject to the option are vested and exercisable as of the date hereof.